3 April 2024 - AB Science today announced that Health Canada has granted eligibility for reconsideration request for masitinib in ...
8 April 2024 - Purdue Pharma announced today that FDA has accepted for filing the company’s new drug application for the ...
9 April 2024 - Lundbeck and Otsuka have submitted a supplemental new drug application for US FDA review of brexpiprazole ...
9 April 2024 - Syros Pharmaceuticals today announced that the US FDA has granted fast track designation to tamibarotene in ...
9 April 2024 - It is common for treatments to yield different outcomes in different patients. If patient characteristics that predict ...
8 April 2024 - Dovato is now the first and only oral, two drug, single-tablet regimen available for people aged 12 ...
8 April 2024 - Second FDA acceptance for an NDA filing by Shorla Oncology announced in 2024. ...
8 April 2024 - Supernus Pharmaceuticals today announced a regulatory update for SPN-830. ...
8 April 2024 - If approved, elamipretide would become the first approved therapy for Barth syndrome. ...
8 April 2024 - Phanes Therapeutics announced today that the US FDA has granted fast track designation to PT217 for the ...
3 April 2024 - Submission of complete response letter response triggers up to six month review period by the FDA. ...
5 April 2024 - The EMA said in a new reflection paper that it will consider granting conditional marketing approval ...
7 April 2024 - In this cohort study of cancer drugs granted accelerated approval from 2013 to 2017, 41% (19/46) did ...
7 April 2024 - Dizal today announced that the US FDA has granted breakthrough therapy designation to its sunvozertinib as ...
5 April 2024 - Today, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with ...